Integrative multi-omics identifies DOC2A as a novel pharmacological target for bipolar disorder - PubMed
an hour ago
- #therapeutic target
- #multi-omics
- #bipolar disorder
- Integrative multi-omics identified DOC2A as the top candidate gene associated with bipolar disorder (BD) through proteome-wide association studies (PWAS).
- Bayesian colocalization and summary-data-based Mendelian randomization (SMR) supported a causal link between DOC2A and BD, with decreased expression observed in various brain cell types and regions in BD patients.
- DOC2A was found to regulate co-expression networks related to BD-associated processes like neurotransmitter secretion and postsynaptic actin cytoskeleton organization.
- Molecular docking indicated that DOC2A can bind with favorable affinity to BD-related drugs and neuroprotective compounds, suggesting potential as a therapeutic target.